RPRX Stock Price, News and Analysis
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Market Cap: $19,325,963,587.32
Industry: PHARMACEUTICAL PREPARATIONS
Track RPRX stock with real-time alerts and market analysis
Current Price: $45.12
Royalty Pharma plcs
$45.12
-0.64%$-0.29
Major market announcement affects tech stocks across all sectors
Earnings report shows significant growth in quarterly revenue
Regulatory changes impact industry outlook for upcoming quarter